GlassScriptPhysician profile
Christine Hatch
NPI 1831304138
$11,407.15
in general payments reported to CMS, 2019-2025
58 companies · $259 in 2025
The $259 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,195 · 2022: $2,336 · 2023: $3,338 · 2024: $2,279 · 2025: $259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,785 · Education: $91.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,784.66 |
| Education | $91.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,669.92 | 2021-2025 | |
| Lundbeck LLC | $664.80 | 2021-2025 | Vyepti, Rexulti |
| Astrazeneca Pharmaceuticals LP | $620.92 | 2021-2024 | Farxiga, Breztri |
| Novo Nordisk INC | $594.26 | 2021-2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $588.58 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $535.45 | 2021-2024 | Jardiance, Mounjaro, Emgality |
| Pfizer INC. | $495.60 | 2021-2024 | |
| Astellas Pharma US INC | $421.32 | 2021-2023 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $395.00 | 2021-2024 | Synjardy, Jardiance, Tradjenta |
| Takeda Pharmaceuticals U.S.A., INC. | $387.52 | 2021-2023 | Cuvitru |
| Corium, LLC | $373.71 | 2022-2024 | Azstarys |
| Janssen Pharmaceuticals, INC | $343.09 | 2021-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $333.85 | 2021-2024 | |
| Sumitomo Pharma America, INC. | $293.93 | 2023-2024 | Gemtesa |
| Amgen INC. | $287.80 | 2021-2024 | Repatha, Otezla, Evenity |
Show all 58 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Hatch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.